# Notes for the project introduction

## Paper that provided in vitro evidence to support this work
https://pmc-ncbi-nlm-nih-gov.ezproxy.galter.northwestern.edu/articles/PMC9002105/

## Related papers for the project

# Academic Papers on Digestible Carbohydrates, Metabolic Syndrome, and Obesity

## Resistant Starch and Metabolic Health

### Short-Chain Fatty Acid Production and Weight Management

Several recent studies demonstrate that resistant starch (RS) supplementation significantly improves metabolic parameters through gut microbiota modulation. A 2024 randomized controlled trial showed that 8 weeks of RS supplementation achieved a mean weight loss of 2.8 kg and improved insulin resistance in overweight individuals. The benefits were associated with changes in gut microbiota composition, particularly increases in *Bifidobacterium adolescentis*, which mechanistically alters bile acid profiles, reduces inflammation through intestinal barrier restoration, and inhibits lipid absorption.[1][2][3]

A comprehensive meta-analysis of 36 randomized controlled trials involving 982 participants found that resistant starch types 1 and 2 lowered acute postprandial blood glucose and chronic postprandial glucose responses. Resistant starch type 2 also improved acute postprandial insulin response and chronic fasting glucose and insulin levels. The effects were particularly pronounced in diabetic patients with overweight or obesity compared to prediabetic individuals.[4]

### Visceral Fat Reduction and Glucose Control

Research demonstrates that RS intake significantly reduces abdominal adiposity without changes in total body weight. Studies show RS supplementation can reduce visceral fat area by up to 27% and subcutaneous fat area by 10.9% compared to control starch. The intervention also increased early-phase insulin, C-peptide, and GLP-1 secretion while decreasing LDL cholesterol levels.[5]

## Beta-Glucan and Glycemic Control

### Molecular Weight-Dependent Effects

High-molecular-weight (HMW) oat β-glucan demonstrates superior glycemic control compared to low-molecular-weight variants. A systematic review and meta-analysis of 103 trial comparisons found that β-glucan reduced glucose incremental area-under-the-curve (iAUC) by 23% and insulin by 22%. The effects showed significant molecular weight dependence: β-glucan with MW ≥1000 kg/mol reduced glucose iAUC by 8% per gram, while MW <300 kg/mol showed minimal effects.[6][7][8]

The dose-response relationship is linear, with each gram of oat β-glucan per 30g available carbohydrate reducing glucose iAUC by 8%, glucose peak by 9%, and insulin by 10-11%. For high MW β-glucan, clinically meaningful ≥20% reductions in glucose response can be achieved with as little as 2.9g per 30g available carbohydrate. Even a 2g dose of high MW (800 kDa) β-glucan can reduce acute glucose peak responses.[9][8][6]

### Metabolic Syndrome Applications

Studies in metabolic syndrome patients show that β-glucan supplementation improves multiple cardiovascular risk factors. Animal studies demonstrate that oat β-glucan supplementation (200-500 mg/kg body weight) significantly reduced insulin resistance, with high-dose treatment showing more pronounced effects similar to metformin. The improvements were associated with increased hepatic glucokinase activity and enhanced glucose utilization. Long-term studies indicate that mediate-term oat β-glucan intake (3-8 weeks) favors glycemic control in type 2 diabetes patients.[10][11]

## Slowly Digestible Starch (SDS)

### Glucose Homeostasis in Diabetes

Recent research highlights SDS as an underutilized intervention for diabetes management. A 2024 comprehensive review found that SDS displays beneficial effects on reducing glucose excursions in healthy, insulin-resistant, and type 2 diabetic individuals. SDS induces a slow and prolonged glucose release, resulting in reduced postprandial glycemic responses and extended glycemic index values.[12][13]

In type 2 diabetic patients, 1 week of SDS-rich diet (60g/day) reduced several glycemic variability parameters: standard deviation lowered by 17% and mean amplitude of glucose excursions (MAGE) by 23%. These parameters correlate with HbA1c, suggesting potential for long-term glycemic improvement.[12]

### Prediabetic and At-Risk Populations

A 3-week intervention with 17.9g SDS per 100g biscuit in at-risk individuals significantly reduced fasting blood glucose and postprandial glucose and insulin responses while maintaining matched carbohydrate content. The intervention also reduced low-grade inflammatory parameters, highlighting SDS's broader metabolic benefits. Studies show that foods with the highest SDS content (23.9-27.5 g/100g) induce the lowest glycemic responses with the lowest incremental AUC of glucose and insulin concentration.[12]

Animal studies demonstrate that slowly digestible carbohydrate (SDC) intervention significantly lowered fasting blood glucose, glycated hemoglobin levels, and glucose AUC, indicating improved glycemic control and glucose tolerance. SDC also elevated pancreas index, decreased insulin and glucagon release, reduced HOMA-IR, and increased insulin sensitivity.[14]

## Polyphenols and Insulin Resistance

### Mechanistic Pathways

Polyphenols improve insulin resistance through multiple mechanisms including lowering postprandial glucose, modulating glucose transport, affecting insulin signaling pathways, and protecting pancreatic β-cells. A compelling body of evidence suggests that dietary polyphenols represent an important alternative for type 2 diabetes management due to their multifaceted actions on glucose homeostasis.[15]

Recent meta-analyses demonstrate that polyphenol supplementation results in significant decreases in serum insulin levels (MD -2.49 [-3.72, -1.25] 95% CI; p < 0.0001) and BMI reduction (MD -0.12 [-0.18, -0.06] 95% CI; p = 0.0002). Clinical trials consistently show improvements in HbA1c, fasting blood glucose levels, and insulin resistance markers.[16][15]

### Gut Microbiota Modulation

Polyphenols interact with gut microbiota and exert strong regulatory effects on intestinal bacteria, improving systemic inflammation and insulin sensitivity. Different polyphenolic compounds can increase GLP-1 secretion from L-cells and naturally suppress DPP-IV activity, potentially increasing GLP-1 half-life and stimulating glucose-dependent insulin secretion. Studies show that polyphenol administration may accelerate the catabolism of branched-chain amino acids, lowering circulating BCAA levels and improving glucose homeostasis and insulin sensitivity.[15]

## Oligosaccharides and Gut Microbiota

### Prebiotic Effects on Metabolic Health

Oligosaccharides function as prebiotics, promoting beneficial bacteria growth that produces short-chain fatty acids (SCFAs) affecting energy metabolism, absorption, and intestinal permeability. These compounds stimulate SCFA production through GPR41/43 receptor activation, regulating gut motility, reducing inflammation, and promoting insulin sensitivity.[17]

Recent studies on pectin oligosaccharides (POS) demonstrate significant improvements in lipid metabolism. POS supplementation promoted the growth of cholesterol-related bacterial groups *Bacteroidetes*, *Bifidobacterium*, and *Lactobacillus* while decreasing conditional pathogenic bacteria. The intervention significantly increased concentrations of cholesterol metabolism-related metabolites (adenosine monophosphate, cyclic adenosine monophosphate, guanosine, and butyrate).[18]

### Arabinoxylans and Metabolic Control

Arabinoxylan supplementation shows promising effects on metabolic syndrome parameters. Studies in subjects with impaired glucose tolerance found that 15g arabinoxylan supplementation for 6 weeks resulted in lower postprandial responses in serum glucose, insulin, and triglycerides. The intervention also reduced total plasma ghrelin by 42±8 pg/ml, though acylated ghrelin responses were unchanged.[19]

In type 2 diabetic patients, 15g/day arabinoxylan-rich fiber supplementation for 5 weeks significantly lowered fasting and 2-hour plasma glucose, 2-hour insulin, and serum fructosamine levels. Animal studies demonstrate that arabinoxylan treatment increased fiber-degrading bacteria, enhanced short-chain fatty acid production, and decreased opportunistic pathogens. The intervention also improved carbohydrate, lipid, and amino acid metabolism in diabetic rats.[20][21][22][23]

### Mannan-Oligosaccharides and Weight Management

Mannan-oligosaccharides (MOS) demonstrate significant anti-obesity effects through gut microbiota modulation. Studies show that MOS supplementation (100-200 mg/kg/day) significantly reduces body weight gain, insulin resistance, fatty liver, and inflammatory responses in obese mice. MOS stimulates lipolysis and inhibits lipogenesis in adipose tissues while restructuring the gut microbiome by enhancing *Bifidobacterium* and *Lactobacillus* abundance.[24][25]

The appetite suppression and lipid-lowering effects of MOS are highly correlated with increased butyrate levels. MOS supplementation decreases the Firmicutes/Bacteroidetes ratio and reverses high-fat diet-induced changes in beneficial bacterial species including *Akkermansia muciniphila*, *Bacteroides acidifaciens*, *Lactobacillus gasseri*, and *Bifidobacterium pseudolongum*.[25][24]

## Clinical Applications and Dosing

### Evidence-Based Recommendations

For resistant starch, effective doses range from 15-60g daily for improving insulin sensitivity and glucose control. Meta-analyses show that RS type 1 and 2 are most effective, with type 2 showing benefits at doses of 6-40g per day. Clinical trials typically demonstrate effects within 1-8 weeks of supplementation.[4][12]

For oat β-glucan, the European Food Safety Authority recommends minimum 4g per 30g available carbohydrate, though high MW β-glucan can be effective at lower doses (2.9g per 30g carbohydrate). Studies show dose-dependent effects with each gram reducing glucose responses by 8-9%.[8][6]

Slowly digestible starch shows benefits at 17-60g daily, with effects observable within 1-3 weeks. For polyphenols, effective interventions typically provide concentrated extracts equivalent to significant dietary sources, showing consistent improvements in glucose control and insulin sensitivity.[16][15][12]

Pectin oligosaccharides demonstrate prebiotic effects and cholesterol-lowering benefits, with studies showing increased beneficial bacteria and improved metabolite profiles. Arabinoxylan supplementation at 15g daily improves glycemic control in type 2 diabetes and metabolic parameters in prediabetic individuals. Mannan-oligosaccharides show anti-obesity effects at doses of 100-200 mg/kg in animal studies, with human applications requiring further research.[22][23][18][24][25][19]

## Future Research Directions

Current evidence supports the therapeutic potential of various digestible carbohydrates for metabolic syndrome and obesity management. However, research gaps remain regarding optimal dosing, duration of interventions, individual variability based on gut microbiota composition, and long-term sustainability of benefits. Future studies should focus on personalized nutrition approaches, investigating synergistic effects of combined interventions, and establishing standardized protocols for clinical application.

The evidence consistently demonstrates that carbohydrate quality, rather than quantity alone, plays a crucial role in metabolic health. Interventions targeting slowly digestible carbohydrates, resistant starches, high-molecular-weight β-glucans, and prebiotic oligosaccharides offer promising strategies for diabetes prevention and obesity management through mechanisms involving improved insulin sensitivity, enhanced satiety, favorable gut microbiota modulation, and optimized metabolic flexibility.

[1] https://www.medicalnewstoday.com/articles/resistant-starch-diet-may-aid-weight-loss-boost-insulin-sensitivity
[2] https://www.nature.com/articles/s42255-024-00988-y
[3] https://www.news-medical.net/news/20240227/Resistant-starch-diet-proves-a-game-changer-for-weight-loss-and-diabetes-control.aspx
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC10085630/
[5] https://www.sciencedirect.com/science/article/pii/S216183132200641X
[6] https://pmc.ncbi.nlm.nih.gov/articles/PMC8563417/
[7] https://www.nature.com/articles/s41430-022-01176-5
[8] https://www.nature.com/articles/s41430-021-00875-9
[9] https://pubs.rsc.org/en/content/articlehtml/2025/fo/d5fo00353a
[10] https://pmc.ncbi.nlm.nih.gov/articles/PMC3871839/
[11] https://pmc.ncbi.nlm.nih.gov/articles/PMC4728652/
[12] https://pmc.ncbi.nlm.nih.gov/articles/PMC11155281/
[13] https://pubmed.ncbi.nlm.nih.gov/38836807
[14] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.854725/full
[15] https://pmc.ncbi.nlm.nih.gov/articles/PMC10921170/
[16] https://academic.oup.com/jes/article/7/Supplement_1/bvad114.1541/7290941
[17] https://academic.oup.com/jcem/article/109/11/2709/7718329
[18] https://pmc.ncbi.nlm.nih.gov/articles/PMC11243408/
[19] https://www.nature.com/articles/1602525
[20] https://pubmed.ncbi.nlm.nih.gov/34543925/
[21] https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.201800222
[22] https://pubmed.ncbi.nlm.nih.gov/15042130/
[23] https://www.nature.com/articles/1601857
[24] https://pubmed.ncbi.nlm.nih.gov/29974116/
[25] https://pubmed.ncbi.nlm.nih.gov/31487425/
[26] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1516086/full
[27] https://www.tandfonline.com/doi/full/10.1080/09540105.2025.2491597
[28] https://pmc.ncbi.nlm.nih.gov/articles/PMC2663451/
[29] https://www.biorxiv.org/content/biorxiv/early/2025/03/01/2024.07.04.602078.full.pdf
[30] https://www.sciencedirect.com/science/article/pii/S1756464622003668
[31] https://pmc.ncbi.nlm.nih.gov/articles/PMC12026447/
[32] https://www.ncbi.nlm.nih.gov/books/NBK459248/
[33] https://pmc.ncbi.nlm.nih.gov/articles/PMC5294823/
[34] https://www.sciencedirect.com/science/article/abs/pii/S0924224418307489
[35] https://www.sciencedirect.com/science/article/pii/S2589936825000313
[36] https://www.uhhospitals.org/blog/articles/2025/01/improve-your-gut-health-with-resistant-starch
[37] https://link.springer.com/article/10.1007/s42452-024-05968-1
[38] https://pubmed.ncbi.nlm.nih.gov/39519522/
[39] https://www.abbott.com/corpnewsroom/nutrition-health-and-wellness/low-gi-foods-why-they-matter-for-glucose-levels.html
[40] https://pmc.ncbi.nlm.nih.gov/articles/PMC11557335/
[41] https://www.tandfonline.com/doi/full/10.1080/10408398.2024.2400235
[42] https://www.sciencedirect.com/science/article/pii/S2161831324001807
[43] https://www.sciencedirect.com/science/article/abs/pii/S0144861725003777
[44] https://www.sciencedirect.com/science/article/pii/S0002916523030460
[45] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1376508/full
[46] https://www.cambridge.org/core/journals/nutrition-research-reviews/article/nutrition-and-health-effects-of-pectin-a-systematic-scoping-review-of-human-intervention-studies/01BF0759F09A2BBC419F333B8B1D4FF9
[47] https://www.sciencedirect.com/science/article/pii/S0141813025071144
[48] https://www.sciencedirect.com/science/article/abs/pii/S1568163724002344
[49] https://onlinelibrary.wiley.com/doi/10.1111/jdi.14139
[50] https://www.endocrine-abstracts.org/ea/0110/ea0110ep485
[51] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.863657/full
[52] https://www.webmd.com/vitamins/ai/ingredientmono-1455/arabinoxylan
[53] https://www.scielo.br/j/cta/a/cryy4DTjnYhLrk5Z7CxdvNK/?format=pdf&lang=en
[54] https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2016.00129/full
[55] https://www.sciencedirect.com/science/article/abs/pii/S0889159121001628
[56] https://www.sciencedirect.com/science/article/pii/S2214799322001096
[57] https://www.sciencedirect.com/science/article/pii/S2352513423002594
[58] https://onlinelibrary.wiley.com/doi/10.1155/2012/851362
[59] https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0159223

## Project Description - Lurie & Abbott Collaboration
Project 2 – Interpersonal variation in energetics and short-chain fatty acid production of obesity-associated gut microbiota to slow and fast digestible carbohydrates
Obesity continues to increase as a public health emergency. With the origins of most adult obesity being in childhood, effective clinical approaches are urgently needed to prevent or reverse childhood obesity.

The gut-associated microbiome is an established central factor in energy harvest, hepatic function, insulin sensitivity, and adipose tissue homeostasis. In comparison to fast digestible carbohydrate (FDC) sources, the Abbott group has shown in a murine model of obesity that nutrition with slow digestible carbohydrates (SDC) reverses obesity-associated phenotypes, including elevated body mass, insulin resistance, and systemic inflammation. Lurie investigators and colleagues have shown interpersonal variation in the production of short-chain fatty acids (SCFA) by the human gut microbiome from adolescents with obesity in response to ex vivo prebiotic exposure, suggesting the complex carbohydrate utilization of the microbiota varies between individuals and thus may affect who responds to SDC and other nutritional approaches to obesity.

The interpersonal differences in SDC responses by the childhood-associated human microbiota may not be fully predicted in the murine obesity model. Understanding the variation in the compositional and metabolic responses of the childhood-associated microbiota may inform future obesity-treatment trials and precision approaches to obesity therapy.

The main objectives of this project are to measure variation in the responses between different human gut-associated microbiome communities to FDC and SDC and to identify childhood-associated organisms with facile utilization of SDC.

The following aims will be pursued to address the main objectives:

Aim 1. Test interindividual variation of short-chain fatty acid production among fecal microbiota samples to slow and fast digestible carbohydrates.
Here we will test fecal microbiota samples from adolescents with obesity before and after ex vivo exposure to different sole carbohydrate sources for butyrate, propionate, and acetate using gas chromatography. We will compare the SCFA production relative to untreated and prebiotic GFA-treated samples. Twenty prospectively collected fecal samples from healthy weight adolescents and adolescents with obesity (n=40 total) will be tested.

Timeline: 9 months

Aim 2. Measure energy harvest differences between human obesity-associated fecal microbiota.
Fecal samples from adolescents with and without obesity will be exposed ex vivo to SDC and FDC. Timepoint samples will be collected from the ex vivo grown communities and will be subjected to bomb calorimetry to calculate the per gram sample kcal. Twenty prospectively collected fecal samples from healthy weight adolescents and adolescents with obesity (n=40 total) will be tested.

Timeline: 6 months

Aim 3. Isolate SDC bacterial utilizers using single cell isolation techniques towards the future goal of creating obesity treatment synbiotic combinations.
Using fecal samples from individuals with high SCFA production and low energy extraction upon ex vivo treatment with SDC, high dimensional single bacteria cell capture will be performed and arrayed into libraries. Growth of individual strains in response to SDC and FDC will be measured and compared to standard non-SDC utilizing E. coli controls.

Timeline: 12 months

Impact
Understanding the interpersonal differences in SDC utilization by the childhood-associated human microbiota may inform future obesity-treatment trials through the identification of likely responders and, subsequently, precision approaches to obesity therapy.